Drug combinations with methotrexate to treat rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Rath, T ^a   Rubbert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Combination drug therapy; Disease modifying anti rheumatic drugs; Immunosuppressive agents; Methotrexate; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; AMINOTRANSFERASE;

ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE RADIOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DAS28; DRUG RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78650569574     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: MTX as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:179-85.
2. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of MTX in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009;68:1086-93.
3. BRAUN J, RAU R: An update on MTX. Curr Opin Rheumatol 2009;21:216-23.
4. ALARCON GS, TRACY IC, BLACKBURN WD Jr: MTX in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
5. SMOLEN JS, ALETAHA D, BIJLSMA JWJ et al.: for the T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
6. GOEKOOP Y, ALLAART C, BREEDVELD F, DIJKMANS B: Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001;13:177-83.
7. SCOTT DL, FARROW S, YEO SI: Early developments in combination therapy. Clin Exp Rheumatol 1999;17: S8-12.
8. FELSON DT, ANDERSON JJ, MEENAN RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994;37:1487-91.
9. O'DELL J: Combination DMARD therapy for rheumatoid arthritis: apparent universal acceptance. Arthritis Rheum 1997;40:50. [abstract]
10. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762.
11. KATCHAMART W, TRUDEAU J, PHUMETHUM V, BOMBARDIER C: Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010 April 14; 4. CD008495. Review.
12. KATCHAMART W. TRUDEAU J. PHUMETHUM V, BOMBARDIER C: The efficacy and toxicity of MTX monotherapy vs. MTX combination therapy with non-biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2009;68:1105-12
13. GAUJOUX-VIALA C, SMOLEN JS, LANDEWÉ R et al.: Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
14. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of MTX: A randomized, double-blind, placebo-controlled trial. Ann Int Med 2002;137:726-33.
15. KREMER JM, GENOVESE MC, CANNON GW: Combination leflunomide and MTX therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomised, double-blind, placebo controlled trial. J Rheumatol 2004;31:1521-31.
16. MROCZKOWSKI PJ, WEINBLATT ME, KREMER JM: MTX and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol 1999;17(Suppl. 18):66-8.
17. LEE SS, PARK YW, PARLK JJ et al.: Combination treatment with leflunomide and MTX for patients with active rheumatoid arthritis. Scand J Rheumatol 2009;38:11-4.
18. YOCUM D: Immunological actions of cyclosporine A in rheumatoid arthritis. Br J Rheumatol 1993;32(Suppl. 1):38-41
19. FERRACCIOLI GF, BAMBARA LM, FERRARIS M et al.: Effects of cyclosporin on joint damage in rheumatoid arthritis. Clin Exp Rheumatol 1997;15(Suppl. 17):83-9.
20. PASERO G, PRIOLO F, MARUBINI E et al.: Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;37:1006-15.
21. FØRRE Ø and THE NORWEGIAN ARTHRITIS STUDY GROUP: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin: results of a 48-week multicenter study comparing low-dose cyclosporin with placebo. Arthritis Rheum 1994;37:1506-12.
22. DROSOS AA, VOULGARI PV, KATSARAKI A, ZIKOU AK: Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol Int 2000;19:113-8.
23. CHOY EH, SMITH CM, FAREWELL V et al.: Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67:656-63.
24. MARCHESONI A, BATTAFARANO N, ARREGHINI M et al.: Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and MTX with MTX alone. Rheumatology 2003;42:1545-9.
25. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and MTX in severe rheumatoid arthritis. The MTX-Cyclosporine Combination Study Group. N Engl J Med 1995;333:137-41.
26. STEIN CM, PINCUS T, YOCUM D et al.: Combination treatment of severe rheumatoid arthritis with cyclosporine and MTX for forty-eight weeks. Arthritis Rheum 1997;40:1843-51.
27. WILLKENS RF, SHARP JT, STABLEIN D, MARKS C, WORTMANN R: Comparison of azathioprine, MTX, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995;38:1799-806.
28. BLANCO R, MARTINEZ-TABOADA VM, GONZALEZ-GAY MA et al.: Acute febrile toxic reactions in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996;39:1016-20.
29. LEHMAN AJ, ESDAILE JM, KLINKHOFF AV et al.: A 48-week, randomized, doubleblind, double-observer, placebo-controlled multicenter trial of combination MTX and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005;52:130.
30. CAPELLI HA, MADHOK R, PORTER DR et al.: Combination therapy with sulfasalazine and MTX is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007;66:235-41.
31. DOUG ADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulfasalazine and MTX compared with single components. Ann Rheum Dis 1999;58:220-5.
32. O'DELL JR, LEFF R, PAULSEN G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164.
33. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with MTX alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. A' EnglJMed 1996;334:1287-91.
34. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568.
35. KORPELA M, LAASONEN L, HANNONEN P et al.: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072.
36. RANTALAIHO V, KORPELA M, LAASONEN L et al. for the FIN-RACo TRIAL GROUP: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010;24; 12:122.
37. KARSTILA KL, RANTALAIHO VM, MUSTONEN JT et al. for the FIN-RACO TRIAL GROUP: Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Clin Exp Rheumatol 2010;28:73-8.
38. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
39. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with MTX in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open label trial). Ann Rheum Dis 2007;66:1443-9.
40. GOEKOOP-RUITERMAN Y P M, DE VRIESBOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
41. LANDEWÉ RB, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
42. VAN TUYL L H D, VOSKUYL AE, LEMS WF et al.: Rate of progression of the COBRA trial cohort after 11 years follow up [abstract no. 2000]. ACR Annual Scientific Meeting 2008.
43. KLARENBEEK NB, ALLAART CF, KERSTENS PJ, HUIZINGA TW, DIJKMANS BA: The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009;21:291-8.
44. VAN VOLLENHOVEN RF, ERNESTAM S, GEBOREK P et al.: In patients with early RA who fail initial MTX, the addition of anti-TNF yields better ACR and EULAR responses than the addition of conventional DMARDs: 1-years results of the SWEFOT trial [abstract no. 1003]. ACR Annual Scientific Meeting 2008.